© 2021 Marker Therapeutics, Inc.
Peter L. Hoang to present a corporate overview at the upcoming Phacilitate Leaders World & World Stem Cell Summit 2019 on January 23, 2019.
Data from four abstracts—including three oral presentations—were accepted for presentation at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research 2019.
The Houston, Texas-based immuno-oncology group gave an update on five clinical trials.
The Company has announced a year-end update in five clinical trials using the Company’s therapeutic products, LAPP and MAPP multi-antigen targeted T cell (MultiTAA) therapies and TPIV200, its Folate Receptor Alpha (FRα) peptide cancer vaccine product candidate.